Insulin ELISA

(10-1113-01)

Kit format: 1 x 96 wells

Measurement range: 3 - 200 mU/L (0.13 - 8.70 µg/L)

Calibrated against 1st International Reference Preparation 66/304 for human insulin

No cross-reactivity to C-peptide or Proinsulin des(31-32) or split (32-33)

Insignificant or no cross-reactivity to insulin analogs

CE/IVD labeled on select markets

Serum controls available: 10-1134-01 (US only) or 10-1164-01

TALK TO A PERSON

Description

The Insulin ELISA is a high quality ELISA for specific measurement of human insulin in serum, plasma or cell culture media.

The Mercodia Insulin ELISA has little or no cross-reactivity to insulin analogs, rat or mouse insulin, which enables distinguishing endogenous human insulin, both in patients undergoing treatment with insulin analogs and in rat or mouse models. The Mercodia Insulin ELISAs are the only ELISA assays to satisfy the total error requirements in the Insulin Standardization Program.

Mercodia Diabetes Antigen Control (10-1134-01 (US only) or 10-1164-01) is designed to be used as a two-level control in the Insulin ELISA.

Test characteristics

Species

Human

Samples

Serum, plasma, cell culture media

Sample volume

25 µL

Assay range

3 - 200 mU/L (0.13 - 8.70 µg/L)

Detection limit

≤ 1 mU/L (0.043 µg/L)

Incubation

1 h + 15 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

C-peptide

<0.01 %

Proinsulin

<0.01 %

Proinsulin des (31-32)

<0.5 %

Proinsulin split (32-33)

<0.5 %

Proinsulin des (64-65)

98 %

Proinsulin split (65-66)

56 %

Insulin aspart

4 %

Insulin detemir

Not detected

Insulin glargin

24 %

Insulin glulisine

Not detected

Insulin lispro

Not detected

IGF-I

<0.02 %

IGF-II

<0.02 %

Rat insulin

0.7 %

Mouse insulin

0.3 %

Porcine insulin

93 %

Ovine insulin

48 %

Bovine insulin

31 %

directions for use & Safety Data Sheet

Directions for Use - 10-1113-01 Version 18.0 Lot.no 35454, 35586

Safety Data Sheet - 10-1113-01

For other languages and older versions:

Technical Library

references

Miller, W. G., Thienpont, L. M., Van Uytfanghe, K., Clark, P. M., Lindstedt, P., Nilsson, G., & Steffes, M. W. (2009). Toward standardization of insulin immunoassays. Clinical Chemistry, 55(5), 1011–1018. Read more >

Fraser, A. et al. (2012) Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation 125, 1367–1380. Read more >

Bauer, S. et al. (2017) Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model. Sci. Rep. 7, 14620. Read more >

Levet, S. et al. (2017) An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes. JCI insight, 2(17). Read more >

Rayner, C. K. et al. (2018) Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes. Diabetes, Obes. Metab. 21, 640–647. Read more >

Fang, Z. et al. (2019) Single-Cell Heterogeneity Analysis and CRISPR Screen Identify Key β-Cell-Specific Disease Genes. Cell Rep. 26, 3132-3144.e7. Read more >